Full Press Release Details
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034)
BIOMED ANNOUNCES TWO ACCEPTED ABSTRACTS FOR PRESENTATION AT ISCT
SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company )
announces that two abstracts related to research and development of CVac have been accepted by the
International Society for Cellular Therapy (ISCT) for presentation at its 19th annual meeting in Auckland, New Zealand from 22-25 April 2013.
The two poster presentations
Dr. Gargosky s poster will describe the use of intracellular cytokine staining (ICS) assays to
measure mucin 1-specific T cells in patient s peripheral blood mononuclear cells (PBMC). Dr. Buchholtz s poster will describe the process of developing and qualifying the COSTIM assay to assess the potency of a product like CVac .
posters will be presented during the Immunotherapy, Regenerative Medicine, Translational Process Development and Gene Therapy session on Wednesday, 24 April 2013 from 5:00pm to 6:30pm.
Prima BioMed is a globally active biotechnology company. As a leader in personalized bio-therapeutic products for cancer, Prima is
dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and to maximize value to shareholders. Prima s lead product is CVac , an autologous dendritic cell product currently in clinical trials for ovarian cancer patients who are in remission.
Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000
Phone: +61 2 9276 1224 Fax: +61 2 9276 1284
For further information please contact:
Ms. Jessica Brown, Prima BioMed Ltd.
+1 (919) 710-9061; jessica.brown@primabiomed.com.au
Australia Investor/Media:
Mr. James Moses, Mandate Corporate
+61 (0) 420 991 574; james@mandatecorporate.com.au
Europe Investor/Media:
Mr. Axel M hlhaus, edicto GmbH
+49 (0) 69 905505-52; amuehlhaus@edicto.de
Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000
2 9276 1224 Fax: +61 2 9276 1284